Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for RaphaS Co., Ltd. (214260:KRX), powered by AI.
RaphaS Co., Ltd. is currently trading at ₩9,690. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for RaphaS Co., Ltd. on Alpha Lenz.
RaphaS Co., Ltd.'s P/E ratio is -17.8.
“RaphaS Co., Ltd. trades at a P/E of -17.8 (undervalued) with modest ROE of -16.2%. 3Y revenue CAGR of 10.2% highlights clear growth momentum.”
Ask for details →RaphaS Co., Ltd. is a prominent entity within the healthcare sector, primarily focusing on the research, development, and production of medical devices and innovative healthcare solutions. The company is engaged in creating cutting-edge technologies aimed at improving patient care and outcomes. With a strong emphasis on innovation, RaphaS Co., Ltd. explores various facets of medical technology, from diagnostic equipment to therapeutic devices, serving hospitals, clinics, and healthcare professionals worldwide. The firm strives to enhance efficiency and accuracy in medical practices, contributing significantly to advancements in health services. Operating within a highly regulated industry, RaphaS Co., Ltd. adheres to stringent compliance standards, ensuring its products' safety and efficacy. Its role is vital in promoting healthier lives and advancing medical knowledge through technological innovation and quality healthcare solutions. This positions RaphaS Co., Ltd. as a critical player in the global healthcare industry.
“RaphaS Co., Ltd. trades at a P/E of -17.8 (undervalued) with modest ROE of -16.2%. 3Y revenue CAGR of 10.2% highlights clear growth momentum.”
Ask for details →RaphaS Co., Ltd. (ticker: 214260) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 79 employees. Market cap is $86.5B.
The current price is ₩9,690 with a P/E ratio of -17.82x and P/B of 2.9x.
ROE is -16.20% and operating margin is -12.72%. Annual revenue is $27.2B.